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REVIEW CURRENTOPINION The current therapeutic scenario for relapsed
mantle cell lymphomaopyright © Lippincott Will
www.co-oncology.coma,b aSimone Ferrero and Martin DreylingPurpose of review
Patients with relapsing mantle cell lymphoma (MCL) still represent a demanding challenge for the
hematooncologist. The dismal prognosis and the absence of generally accepted therapeutic standards
hamper the clinical management of such cases. Moreover, the availability of many targeted approaches, in
a field so far missing efficient salvage regimens, challenges current therapeutic algorithms in these patients.
Recent findings
Molecular targeted drugs provide unprecedented response rates in relapsed and even chemorefractory
MCL. Many phase II studies demonstrated impressive antilymphoma activity of compounds such as
bortezomib, lenalidomide and temsirolimus, whereas ongoing phase III trials currently assess the ‘real
world’ benefit and the impact on survival, both alone and in combination with chemotherapy or
monoclonal antibodies. Recently, the Bruton’s tyrosine kinase inhibitor ibrutinib, targeting the B-cell receptor
cascade, showed impressive response rates and will be soon available in phase III trials.
Summary
In the present review we focus on the major therapeutic discoveries of the last few years to offer a practical
algorithm to select the appropriate treatment in patients with relapsed MCL.
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During the last few years remarkable progress has
been made in the development of new treatment
strategies of mantle cell lymphoma (MCL), an infre-
quent subtype of non-Hodgkin lymphoma charac-
terized by initial high responses but continuous
relapse pattern and a dismal long-term outcome
[1]. Most of the new targeted approaches available
in the clinics or being tested in early phase I/II
protocols result from recent molecular studies on
cell proliferation and apoptosis pathways [2]. More-
over, ongoing molecular genetic investigations con-
tinue to identify new oncogenic targets, providing
preclinical rationale for therapeutic application and
further drugs development [3–5]. Nevertheless, a
definite cure for MCL cannot be achieved so far,
with the exception of potentially harmful allogeneic
stem cell transplantation (allo-SCT). Even more
important a satisfactory disease control can be
achieved only in a subset of patients, particularly
in relapsed disease.
The major clinical trials of the last decade
focused on improvement of the front-line treat-
ment, leading to the definition of a ‘gold standard’iams & Wilkins. Unauthotherapy, for young and fit patients consisting of
anthracyclines, high doses of cytarabine and rituxi-
mab, followed by an autologous stem cell transplan-
tation (auto-SCT) [6–8,9
&
]. Similar efficiency has
been shown for an even more intensified regime
[10]; however, only the minority of patients was able
to complete the full course in a multicenter setting
[11].
Similarly the standard first-line therapy for eld-
erly MCL patients (not eligible for auto-SCT) has
been lately established consisting of rituximab-
cyclophosphamide-doxorubicin-vincristine-predni-
sone (R-CHOP) immunochemotherapy, followed byrized reproduction of this article is prohibited.
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KEY POINTS
 The major biological discoveries of the last years in
MCL survival pathways have led to the availability in
the clinics of many effective targeted drugs.
 Phase II and III clinical trials are currently ongoing to
test the efficacy of these drugs on large series of
relapsed MCL patients.
 Clinical trials investigating innovative approaches
should be considered in all relapsed MCL patients.
 The treatment strategies in relapsed MCL should
depend on the individual risk profile and
patients’ comorbidities.
Relapsed mantle cell lymphoma Ferrero and Dreylingrituximab maintenance [12]. Both efforts resulted in
a considerable improvement in overall survival.
On the contrary, lacking large randomized
clinical trials, there is still no generally accepted
approach in relapsed MCL. Clinical guidelines,
although recently updated [9
&
], are not specifically
focused on the relapse setting, supplying only some
hints. Moreover, the numerous new targeted
options [2], along with the promising data for com-
binations with conventional chemotherapeutics
and anti-CD20 immunotherapy, could generate
hesitation about the optimal therapeutic approach
for these patients. Thus, the present review focuses
on the major therapeutic discoveries of the last few
years to offer a practical algorithm to select appro-
priate treatment decisions in patients with relapsed
MCL.CURRENT AVAILABLE THERAPEUTIC
OPTIONS
As no curative treatment can be so far offered to
relapsed MCL patients, aside from allo-SCT, the
therapeutic goal should be the prolonged disease
control, balancing the expected efficacy with the
risk of toxicity and reduced quality of life (QoL). In
this perspective the most recent data on salvage
regimens are discussed below.Chemotherapy-based approaches
The addition of rituximab to conventional chemo-
therapy (R-FCM, R-GEMOX, R-DHAP) increases
response rates up to 60–70%; however, the duration
of response in relapsing disease remains limited
(mainly less than 1 year) and such treatment options
should be considered basically palliative [13–15].
More promising data on the contrary have been
recently achieved from the new combination ofCopyright © Lippincott Williams & Wilkins. Unau
1040-8746  2013 Wolters Kluwer Health | Lippincott Williams & Wilksome ‘old drugs’ with rituximab, based on the
results of the bendamustin-rituximab regimen
(75% overall response rate, ORR – and 50% com-
plete responses, CR – in relapsing disease) [16]. The
impressive activity of bendamustin-rituximab has
been also shown in first-line treatment [17], as well
as the superior data of cytarabine in first-line young
patients [6–8]. Accordingly, a new regimen com-
bining rituximab, bendamustine and cytarabine
(R-BAC) was tested in 20 relapsed and 20 first diag-
nosed MCL patients [18
&
]. The activity of this com-
bination is noteworthy, although in a limited series:
an ORR of 80 with 70% CR was reported in relapsing
patients (90 and 83% on the total, respectively),
resulting in an excellent 2-year progression-free sur-
vival (PFS) of 70% (95% for the untreated patients).
The primary toxicity was reversible myelosuppres-
sion, platelet transfusions were required in two-third
of cycles and erythropoietin was applied in about half
of patients. Currently, a phase II study of R-BAC in
first-line for elderly patients is ongoing, but this
regimen is promising also in the relapse setting.
In contrast, considering the low efficacy and
the increased toxicity of an auto-SCT approach
in second-line [19], such a treatment should be
offered only to fit MCL patients who did not receive
auto-SCT as first-line. Finally, among palliative
approaches for elderly patients, the efficacy, feasi-
bility and low toxicity of an oral low-dose metro-
nomic polichemotherapy combination (PEP-C) is
noteworthy, optionally in combination with rituxi-
mab and thalidomide [20,21].Established molecular approaches
In this section the most recent data on salvage ‘new
drugs’ regimens are extensively discussed.Proteasome inhibitors
The first ‘new drug’ to be registered in relapsed MCL
in the United States is bortezomib, since the first
demonstrations of this selective and reversible
proteasome 26S inhibitor’s efficacy [22–25]. Even
though the combination of bortezomib with rituxi-
mab and chemotherapy showed high response rates
(up to 60–70%), the majority of these studies consists
of small series of heavilypretreated patients andoften
comprises other histologies. Median PFS rates are in
the range of 12 months. The published combined
regimens encompass both targeted approaches, such
as rituximab or rituximab-dexamethasone [26,27], as
well as immunochemotherapies such as rituximab-
dexamethasone-high dose-cytarabin (R-HAD), rituxi-
mab-prednisone-cyclophosphamide (R-CP), rituxi-
mab-bendamustine and gemcitabine [28–31]. Thethorized reproduction of this article is prohibited.
ins www.co-oncology.com 453
C
Lymphomatoxicity profile predominantly consists of polyneuro-
pathy (sometimes marked and long lasting) and
neutrothrombocytopenia (when associated with
chemotherapy), challenging the long-term appli-
cation, for example, as maintenance in relapsed
MCL. A phase III clinical trial is currently ongoing,
randomizing MCL relapsed patients to receive either
R-HAD bortezomib (NCT01449344). Other studies
tested bortezomib combinations in first-line treat-
ment, too [32–34].Mammalian target of rapamycin inhibitors
Temsirolimus, an intravenous mammalian target of
rapamycin (mTOR) inhibitor, received European
Medicines Agency approval in 2009, due to its
single-agent activity in patients with relapsed MCL.
This approval was based on results of a large phase III
trial in patients with relapsed/refractory MCL. Tem-
sirolimus induced a significant improvement in
median PFS and ORR, compared with investigator’s
choice monotherapy (4.8 versus 1.9 months and 22
versus 2%, respectively) [35]. Hematological adverse
events were the most frequently reported, but were
generally well managed by dose reductions or treat-
ment delay. Gastrointestinal toxicity, especially diar-
rhea, and fatigue were also common, but incidence of
grade 3–4 events was low. The addition of rituximab
to temsirolimus was subsequently tested in a phase II
study on 71 patients. An increased ORR of 59%, with
up to 19% CR was observed, with a median time to
progression (TTP) of about 10 months [36]; the
toxicity profile was similar to temsirolimus mono-
therapy, with a slightly higher rate of pulmonary
toxicity (pneumonia and pneumonitis around 10%
of cases). To further improve its efficacy, temsiroli-
mus is being currently investigated in combination
with bendamustin-rituximab in a phase II clinical
trial (NCT01078142) [37].
Another well tolerated oral mTOR inhibitor is
everolimus. In a multicenter phase II trial of 35
MCL-relapsed patients a ORR of 20% (with 49% of
stable diseases, SD) with a median PFS of 5.5 months
has been reported [38], but further studies in com-
bination with chemotherapy or other biological
drugs are warranted.Immunomodulatory drugs
A number of phase II trials have confirmed the
promising response rates of lenalidomide in
relapsed MCL. This immunomodulatory compound
showed high antilymphoma activity in several other
studies [39–41]. The ORR were around 30–50%,
with promising CR rates up to 20% and PFS gener-
ally around 6–9 months. Recently a phase II study inopyright © Lippincott Williams & Wilkins. Unautho
454 www.co-oncology.com52 patients with relapsed MCL confirmed the
impact of a chemo-free lenalidomide-rituximab
combination with high response rates (57% ORR,
36% CR) and impressive response durations up to
19 months [42
&&
]. On the other hand, no clear
advantages in survival were achieved by the
addition of dexamethasone to lenalidomide [43].
The manageable toxicity (mainly mild, hemato-
logical) and the oral formulation make this drug an
attractive option also in the context of maintenance
regimens, specifically in the elderly population. A
phase II trial of the rituximab-lenalidomide-benda-
mustine combination is presently accruing patients
with relapsed MCL (NCT01737177).
Largely overshadowed by its subsequent follower
lenalidomide, thalidomide, the oldest member of the
immunomodulatory drugs (IMIDs), was shown
active in relapsed MCL already a decade ago [44].
More recently, a retrospective French survey on 58
patients confirmed that thalidomide was effective in
relapsed MCL, with a favorable side-effect profile (7%
grade 3–4 adverse events, including thromboembo-
lism). Although this survey comprised different treat-
ment schedules (monotherapy or combinations with
rituximab or bortezomib), an interesting ORR of 50%
(and 29% SD) with a time to treatment failure (TTF) of
29 and 11% at 1 and 2 years, respectively, should
be noticed [45]. Thus, thalidomide is well tolerated
and might offer a cost-effective alternative to more
expensive targeted agents, especially in countries
with limited health-care resources.Antibody-based approaches
In contrast to its favorable safety profile (mainly
manageable thrombocytopenia and neutropenia)
and promising data coming in other types of lym-
phoma, yttrium-90 (90Y)-ibritumomab tiuxetan
monotherapy does not impact substantially the
prognosis of relapsed MCL. In a phase II trial of
32 patients with relapsed MCL this anti-CD20
radio-immunoconjugate showed an ORR of 32%
with an event-free survival (EFS) of 6 months [46].
However, radioimmunotherapy might be more
efficient as part of multimodal strategies: consider-
ing that the results were particularly poor in patients
with bulky disease, recent studies are exploring the
90Y-ibritumomab tiuxetan consolidation after suc-
cessful salvage chemotherapy or first-line treatment
[47] and the combination with another efficient
targeted drug, such as bortezomib [48].NEW MOLECULAR-TARGETED
APPROACHES
The growing insights into the underlying molecular
biology of MCL form the basis for the ongoingrized reproduction of this article is prohibited.
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Relapsed mantle cell lymphoma Ferrero and Dreylingexploration of targeted approaches [2]. A number of
new compounds are currently being tested in MCL
and are available for application within clinical
trials.B-cell receptor signaling inhibitors
The most convincing data come for the oral Bruton’s
tyrosine kinase (BTK) inhibitor ibrutinib. The
interim results of an international phase II trial on
refractory/relapsed MCL patients show impressive
efficacy and excellent tolerability of this drug,
which specifically blocks the B-cell receptor (BCR)
signaling survival pathway [49
&&
]. In 110 evaluable
patients (either bortezomib exposed or naive) ibru-
tinib monotherapy displayed an impressive ORR of
68%, with 22% CR; the data are even superior focus-
ing on the initial cohort of 51 patients, with a longer
follow-up of nearly 15 months. ORR and CR were
75 and 39%, respectively, clearly demonstrating an
incremental CR rate under continuous treatment.
Median duration of response is not yet reached with
a PFS of around 14 months. Noteworthy is the
favorable safety profile, with less than 15% grade
3/4 hematological toxicity and mainly mild gastro-
intestinal symptoms, fatigue and infections in a
population of heavily pretreated patients. These
outstanding results have already led to the design
of phase III trials, comparing ibrutinib versus tem-
sirolimus in relapsed patients (NCT01646021) or
conventional immunochemotherapy  ibrutinib
as first-line treatment (www.clinicaltrials.gov).
Moreover, the preclinical rationale for BTK-inhibi-
tors combinations with other biological agents
(such as bortezomib) has been already postulated
[50].
Another disruptor of the BCR signal cascade,
CAL-101, a specific inhibitor of phosphatidylinosi-
tol 3-kinase delta isoform, is currently being tested
in phase I/II trials: although achieving a promising
ORR of 62% [51], mature results on remission
duration are not yet available.Antibody-based approaches
New monoclonal antibodies (mAB), targeting a
variety of epitopes in addition to CD20 are currently
investigated in preclinical and clinical trials, but
data on MCL are still scarce. GA101 (obinutuzu-
mab), the first type II, glycoengineered and human-
ized anti-CD20 mAB, determined a ORR of 27%
(four out of 15 patients) in a randomized phase II
trial of refractory/relapsed MCL [52]. Ofatumumab,
a fully human mAB targeting a unique epitope on
the CD20 molecule, has been tested in phase I/II
trials in combination with bendamustine [53] orCopyright © Lippincott Williams & Wilkins. Unau
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missing.
An interesting approach is the bispecific anti-
CD19/anti-CD3 mAB, which showed a high efficacy
in a phase I/II trial particularly in the MCL patients
[55,56].
DCDS4501A is an anti-CD79b mAB conjugated
to a microtubule toxin (monomethyl auristatin E),
showing an acceptable toxicity profile and encour-
aging antitumor activity in a phase I trial on 33
heavily pretreated lymphoma patients, including
four patients with relapsed/refractory MCL [57].
Nevertheless, additional studies on larger patient
cohorts are warranted.Cell cycle/apoptosis targeting drugs and
others
Flavopiridol directly inhibits cyclin-dependent
kinase (CDK) 4 and 6, leading to downregulation
of cyclin D1. This compound showed significant
activity in combination with fludarabine and rituxi-
mab or bortezomib in two phase I trials [58,59]. A
direct CDK4/6 inhibitor, PD0332991, also achieved
substantial responses and suggested clinical benefit
in a subset of MCL patients [60].
ABT-199 is an orally bioavailable, second-gener-
ation BCL-2 specific BH3 mimetic with promising
results in a phase I trial for MCL patients (six out of
six patients with a>50% reduction in target lesions)
[61].
Abexinostat, a novel oral pan histone deacety-
lase inhibitor, proved to be clinically active and well
tolerated in a phase II trial in patients with refrac-
tory/relapsed MCL. ORR was 27% (three out of 11
patients) and PFS 4 months. The most common
grade 3/4 adverse events were thrombocytopenia
(17%), neutropenia (13%), fatigue (13%) and ane-
mia (7%) [62].
A summary of the recent published clinical trials
of targeted approaches in relapsed MCL is presented
in Table 1.ALLOGENEIC TRANSPLANTATION
Despite the high response rates obtained by the new
therapeutic approaches so far described, a long-term
disease control has not yet been achieved in relapsed
MCL and prognosis of subsequent relapses remains
poor, in particular in chemorefractory cases. The
only few reported definite long-term remissions
(or even cure) for at least a selected subset of relapsed
patients are achieved by allo-SCT. The biological
background of such an immunologic approach is
based on a lymphoma-free graft as well as the sup-
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1040-8746  2013 Wolters Kluwer Health | Lippincott Williams & Wilkagainst the tumor, a phenomenon known as ‘graft-
versus-lymphoma’ reaction, potentially overcoming
also chemoresistance. However, the application of
allo-SCT in MCL is hampered by the therapy-related
high toxicity of both reduced-intensity condition-
ing (RIC) and nonmyeloablative (NMA) approaches.
Moreover, limitations come from advanced patient
age (median at diagnosis is 65–68 years), availability
of a compatible donor and the high relapse rate even
after this procedure.
In the retrospective single center experience of
M.D. Anderson [19] 35 most-chemosensitive (88%)
patients (median age 58 years) received a NMA allo-
SCT (fludarabine, cyclophosphamide and high-dose
rituximab). A 6-year PFS rate of 46% was reported,
with a plateau phase after 3 years and no relapse
after 63 months of follow-up, whereas the 6-year
overall survival (OS) was 53%. The 1-year treatment-
related mortality (TRM) rate was 9% but no long-
term nonrelapse mortality (NRM) rate was stated.
A recent retrospective multicenter French report
[63] assessed the outcome of 70 MCL patients (79%
chemosensitive, median age 56 years) receiving a
RIC allo-SCT following various regimens (94%
fludarabine-containing). In this series, the 2-year
EFS and OS rates were 50 and 53%, respectively,
but no plateau phase was achieved at any time point
after transplantation. The 1-year and 2-year TRM
rates were 22 and 32%, respectively.
Interestingly, in a recent large retrospective study
of 202 patients with chemorefractory MCL, the
Center for International Blood and Marrow Trans-
plant Research found no significant differences
between patients receiving conventional and RIC/
NMA allo-SCT in terms of 3-year PFS (20 versus 25%),
OS (25 versus 30%) and NRM (47 versus 43%) [64
&
].
In conclusion, although the discussed studies
may be hampered by selection bias in single center
series, heterogeneity of patients and procedures, it is
noteworthy that an allo-SCT approach achieves
durable remissions in approximately a fourth of
young chemorefractory patients [64
&
]. The addition
of radioimmunotherapy (RIT) to allo-SCT procedures
has shown only conflicting results so far [65,66]. In
conclusion, the issue of tolerability of such an immu-
nological strategy is essential, as the high NRM (along
with the high relapse rate) remains the major limita-
tion for the application of allo-SCT in relapsed MCL.ONGOING EUROPEAN CLINICAL TRIALS
FOR RELAPSED MANTLE CELL
LYMPHOMA
As MCL is a rare entity and relapsed MCL patients
are difficult to treat with conventional immunoche-
motherapy, an enrollment in a prospective clinicalthorized reproduction of this article is prohibited.
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Table 2. Ongoing European clinical trials for relapsed mantle cell lymphoma
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BERT, bendamustine-rituximab-temsirolimus; MCL, mantle cell lymphoma; NCT, national clinical trial; R-HAD  B, rituximab high-dose cytarabine-dexamethasone
 bortezomib; R-2B, rituximab-lenalidomide-bendamustine; R-CHOP, rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone; R-FC, rituximab-fludarabine-
cyclophosphamide. Details of the studies can be found at the internet site: http://www.clinicaltrials.gov
Lymphomatrial is strongly recommended. This option allows
applying new effective and expensive medications,
sometimes not yet exploitable in routine clinical
practice. Thus, a list of the major European actively
recruiting clinical trials for relapsed MCL is reported
in Table 2. The details of each study can be found at:
http://www.clinicaltrials.govProspective, multicenter, randomized, open-
label phase III clinical trials
‘Efficacy and Safety of R-HAD Alone or in Combi-
nation With Bortezomib in Patients With Relapsed
or Refractory MCL’ (NCT01449344), compares the
efficacy and safety of bortezomib in combination
with rituximab, high-dose cytarbine and dexa-
methasone (R-HAD) to R-HAD alone in patients
with relapsed or refractory MCL after or not eligible
for myeloablative treatment. Estimated enrollment:
200 patients. Sponsor: European MCL Network.
‘Study of Ibrutinib (a Bruton’s Tyrosine Kinase
Inhibitor), Versus Temsirolimus in Patients With
Relapsed or Refractory Mantle Cell Lymphoma
Who Have Received at Least One Prior Therapy’
(NCT01646021), evaluates the efficacy and safety
of ibrutinib when compared with temsirolimus in
patients with relapsed or refractory MCL who have
received at least one prior rituximab-containing
chemotherapy regimen. Estimated enrollment:
280 patients. Sponsor: Janssen Research & Develop-
ment LLC.opyright © Lippincott Williams & Wilkins. Unautho
458 www.co-oncology.comProspective, multicenter, single arm, open-
label phase II or I/II clinical trials
‘Temsirolimus, Bendamustine and Rituximab for
Relapsed Follicular Lymphoma or Mantle Cell
Lymphoma’ (NCT01078142): the efficacy of the
combination regimens will be evaluated in a first
cohort of 30 patients with relapsed MCL and in a
second cohort of 30 patients with relapsed follicular
lymphoma. Estimated enrollment: 72 patients.
Sponsor: German Low Grade Lymphoma Study
Group (GLSG) and European MCL Network.
‘Bendamustine/Lenalidomide/Rituximab: Com-
bination as a Second-Line Therapy for First
Relapsed-Refractory MCL’ (NCT01737177), evalu-
ates the safety and activity of the combination
of bendamustine, lenalidomide and rituximab
(R2-B) in patients with first relapsed/refractory
MCL and the efficacy and safety of a maintenance
treatment with lenalidomide for 18 months from
the end of R2-B. Estimated enrollment: 42 patients.
Sponsor: Fondazione Italiana Linfomi ONLUS,
Italy.
‘Escalating Doses of Torisel in Combination
With Three Chemotherapies Regimens: R-CHOP,
R-FC or R-DHA for Patients With Relapsed/Refrac-
tory MCL’ (NCT01389427), assesses the feasibility,
safety and efficacy of temsirolimus in combination
with three chemotherapy regimens. Estimated
enrollment: 63 patients. Sponsor: Groupe Ouest
Est d’Etude des Leucémies et Autres Maladies du
Sang GOELAMS, France.rized reproduction of this article is prohibited.
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Relapsed mantle cell lymphoma Ferrero and DreylingCONCLUSION
Considering the complexities in the treatment of
relapsed MCL, these patients should be generally
referred to experienced centers to determine
the optimal therapeutic strategy and potential
inclusion into a clinical trial. In general treatment
strategies should depend on the individual risk
profile and patients’ comorbidities. Our brief prac-
tical suggestions how to treat a patient with
relapsed MCL are based on the most recent litera-




For young (<65 years) and fit patients allo-SCT
should be considered in all cases after appropriate
first-line therapy, due to its curative potential.
The salvage regimen should contain cytarabine
or bendamustine and rituximab in combination,
when possible, with a targeted approach such as
































Repetition of the p
regime






FIGURE 1. A rational therapeutic algorithm for patients with r
auto-SCT, autologous stem cell transplantation; BERT, bendamustin
C, metronomic prednisone-etoposide-procarbazine-cyclophospham
cytarabine; R-HADB, rituximab high-dose cytarabine-dexamethaso
RIT, radioimmunotherapy; BR, bendamustine-rituximab; R-GEMOX
fludarabine-cyclophosphamide; y, years.
1040-8746  2013 Wolters Kluwer Health | Lippincott Williams & WilkR-HADB, BERT, R-2B regimens). The major goal is
the achievement of at least a partial response,
although a fraction of chemorefractory patients
may obtain prolonged remissions, too. For patients
not eligible for allo-SCT it is crucial to implement
additional consolidation concepts (e.g. rituximab
maintenance, RIT consolidation, new molecules
within studies) to maintain remission.
For elderly (>65 years) fit patients, young
nonfit patients or patients relapsing after allo-SCT
a treatment with curative intent is not established.
A salvage regimen containing targeted approaches
is strongly recommended and the enrollment
into a clinical trial is advisable. A tailored therapy
should be based on individual risk profile, for
example, elevated Ki67 levels [67] may favor a com-
bination of cytarabine and bortezomib (R-HADB)
or plus bendamustine (R-BAC) for fit patients,






























elapsed MCL. allo-SCT, allogeneic stem cell transplantation;
e-rituximab-temsirolimus; Ki67, Ki67 proliferative index; PEP-
ide; PS, performance status; R-BAC, rituximab-bendamustine-
ne-bortezomib; R-2B, rituximab-lenalidomide-bendamustine;
, rituximab-gemcitabine-oxaliplatin; R-FC, rituximab-
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Lymphomain combination with temsirolimus (BERT) or lena-
lidomide (R-2B) appears more suitable for less fit
patients with a lower proliferation index. The repeti-
tion of the prior induction regimen could be an
appropriate approach, if a longstanding remission
(> 2 years) was previously achieved.
For subsequent relapses, along with the deterio-
ration of performance status and QoL, monothera-
pies with targeted drugs (in particular ibrutinib in
the context of a clinical trial, or bortezomib, lena-
lidomide, thalidomide, temsirolimus) or well toler-
ated combinations with rituximab, steroids or low-
dose chemotherapy should be preferred. Oral pallia-
tive combinations, such as the metronomic PEP-C,
could be also useful options in this setting. In
addition, a multidisciplinary palliative support
may be started.
For elderly unfit or frail relapsed patients the
preservation of the QoL should be the primary
objective of the clinical care. Thus, mild oral chemo-
therapy combinations, steroids, radiotherapy and in
selected cases also molecular approaches represent
the standard of care. An adequate palliative support
is crucial.
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